# US 2012/0252886 A1 · Catechins for the treatment of amyloidosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252886 A1
- Document ID: US20120252886A1
- Status: Published application
- Kind: A1
- Application number: 13/462,615
- Filed: 2012-05-02
- Published: 2012-10-04
- Earliest claimed: 2000-12-29
- Inventors: Joel Cummings; Alan D. Snow
- Web page: https://patentgrep.com/patent/US20120252886A1

## CPC

- A61K 31/215: of carboxylic acids
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61K 36/258: Panax (ginseng)
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/80: Scrophulariaceae (Figwort family)
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating an amyloid disease characterized by AL amyloid fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins. The therapeutic amount of the catechin is selected for efficacy in treating AL amyloid fibrillogenesis in a mammalian subject.

## Claims

### Claim 1

A method of treating a disease characterized by AL amyloid deposition, in a mammalian subject, the method comprising administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of epicatechin, epigallocatechin gallate, epigallocatechin, and epicatechin gallate, and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the compound is epicatechin.

### Claim 3

A method of inhibiting AL amyloid deposition in a mammalian subject, the method comprising administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of; epicatechin, epigallocatechin gallate, epigallocatechin, and epicatechin gallate, and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The method of claim 1 wherein the compound is formulated to be administered by a route selected from the group consisting of; oral administration, parenteral injection, intraperitoneal injection, intravenous injection, subcutaneous injection, intramuscular injection, topical administration, and aerosol spray administration.
